Neurology

Phase 3 study seeks to further understand the mechanisms of ocrelizumab.

Impairment is unrelated to how long patients have had MS, study finds.

Acne medication can slow the progression of relapsing-remitting MS in patients who experienced their first symptoms.

Express Scripts implements personal care program aimed at improving medication adherence.

The software helps track Interferon beta-1b injections among MS patients.

Annual relapse rates plummet in patients with multiple sclerosis during extension study.

GatherMS aims to fill the resource knowledge gap in the MS landscape.

Patient with MS was previously treated for 3 years with natalizumab, a known trigger of progressive multifocal leukoencephalopathy.

Synaptic loss in the spinal cord could lead to disability in patients with multiple sclerosis.

Fampyra significantly improved walking and enhanced quality of life in patients with multiple sclerosis.

Ocrevus is the first medication approved for primary-progressive MS. Here's what you should know.

Study will assess improvements in mobility and changes in disability in patients with MS.

Two new reports discuss contraceptive options for patients with multiple sclerosis.

Adult and pediatric multiple sclerosis may have similar risk factors.

Side effects associated with interferon beta for multiple sclerosis highlight the need for additional post-market surveillance for approved drugs.

Interferon beta may increase the risk of stroke, migraine, and depression among patients with multiple sclerosis.

T cells trained to attack Epstein Barr virus may be an effective treatment against multiple sclerosis.

Laquinimod fails to outperform placebo in patients with relapsing-remitting MS.

Health care use before an initial demyelinating event suggests a measureable prodromal period in multiple sclerosis.

New data provides insight into the safety and efficacy of the FDA-approved multiple sclerosis drug.

MedChew Rx is a cannabidiol that treats pain and spasticity associated with multiple sclerosis.

Cellular mechanism may present treatment target for multiple sclerosis.

The first new FDA approval for ALS in 22 years, here's what you should know.

New analyses show the benefits of early treatment with Tefidera (dimethyl fumarate) and Tysabri (natalizumab).

Study shows the importance of evaluating a drug’s ability to address and reduce MS relapses, lesions, disability progression